Márton Kolossváry retweeted
What else is hiding in your #TAVR planning CT? Higher periaortic fat attenuation predicted mortality beyond STS risk, with risk rising exponentially at the top decile (adj HR 3.71). jacc.org/doi/10.1016/j.jcmg.…
#JACCIMG #yesCCT @ErsozluSara @CIRC_MGH @MKolossvary @JanMBrendel
Márton Kolossváry retweeted
Periaortic fat inflammation on preprocedural #TAVR CT, a no-added-cost #cvImaging biomarker, independently predicts long-term mortality post-TAVR. jacc.org/doi/10.1016/j.jcmg.…
#cvVHD #JACCIMG @MKolossvary @JanMBrendel @ErsozluSara @CIRC_MGH @JanMBrendel
Márton Kolossváry retweeted
🚀AI & Innovations Symposium | 9 July @ #SCCT2026 in San Diego. Join global experts to explore how 🤖 AI, advanced 🫀visualisation, & new technologies are reshaping cardiac care. Inc regulation & real-world implementation
#AI #YesCCT Register👉 scct.org/page/SCCT2026specia…
🤖 Made with AI
Márton Kolossváry retweeted
In people with HIV, the risk for major cardiovascular events remains despite statin therapy.
Here, ASCI member Steven K. Grinspoon & team @harvardmed analyze data from the #REPRIEVETrial and find people with HIV may face additional heart disease event risk from the protein ANGPTL3, which affects LDL processing beyond typical lipid problems:
jci.org/articles/view/196021
Márton Kolossváry retweeted
Statin efficacy to decrease #MACE depends on #CAD phenotypes and increases with the extent and severity of disease and in the presence of high-risk plaques. Patients without CAD have no benefit from statin therapy regarding MACE. jacc.org/doi/10.1016/j.jcmg.…
#JACCIMG #cvCAD
Márton Kolossváry retweeted
AHA journals launch the TRUE-AIM report card to promote high-quality, reproducible AI research #AHAJournals ahajournals.org/doi/full/10.…
Transparency, open-science principles🧪, and quality assurance of published AI🧠articles are needed.
Check out the TRUE-AIM report card📄of #AHA that aims to standardize the reporting of AI methods in scientific articles, and will be required from now on:
ahajournals.org/doi/10.1161/…
It was an honor🙏 to lead the development of the TRUE-AIM initiative which aims to standardize the reporting of AI methods in scientific articles. Check out our article below 👇 as it will be required for your AI articles submitted to #AHA journals 🫀
AHA journals launch the TRUE-AIM report card to promote high-quality, reproducible AI research #AHAJournals ahajournals.org/doi/full/10.…
Márton Kolossváry retweeted
High ANGPTL3 contributes to residual risk of major adverse cardiovascular events among people with HIV on statins @jclinicalinvest @SteveGrinspoon @harvardmed @MKolossvary 🇺🇸
jci.org/articles/view/196021
Márton Kolossváry retweeted
For any cardiology fellows interested in training in multimodality CV imaging --> we have an unexpected opening for our 2 year fellowship starting July 1, 2026
Please RT/share #YesCCT #ThinkPET #WhyCMR #EchoFirst #CVImaging #ACCImaging #PCCT
Márton Kolossváry retweeted
Happening now | AI/ML workshop
Experts are diving into how AI/ML are transforming #yesCCT
@MKolossvary @Doc_Tiger @AChoiHeart
Márton Kolossváry retweeted
@MKolossvary #SCCT2025
Nothing is simply better because it's Al, yet to see AI improve patient outcomes in RcTs
Al/ ML models trained on data sets have multiple parameters that can be tuned to achieve optimal performance & will also cause overfitting & results in weak generalizability & performance on unseen (test) data.
Only result from unseen data represent potential generalizability of models
@AHAScience 📝 TRUE-AIM Transparent Reporting & Evaluation of AI Models to set standards
Márton Kolossváry retweeted
Humbled and honored to lead this incredible effort and to see the RVNet(Work) group’s Roadmap published in @NatRevCardiol
Free full text link: rdcu.be/etk00
@ElenaSurkova9 @nicoa002 @oxborough77 @DanXAugustine 🙏🏻Reviewers: @JGrapsa @NAjmoneMarsan @AlexLee_MD
New online! Challenges and opportunities in assessing right ventricular structure and function: a Roadmap for standardization, clinical implementation and research nature.com/articles/s41569-0…
Márton Kolossváry retweeted
📢 Expedited Review for #ESCCongress 2025!
@CircImaging invites authors with accepted ESC presentations to submit manuscripts for rapid review. Initial decisions within 10 days! Submit by June 23 👉 ahajournals.org/circimaging/… #CardioTwitter #CardioImaging @kaznegishi
Márton Kolossváry retweeted
Radiomics – seeing deeper into CCT plaque? Radiomics-based precision phenotyping of coronary plaque morphology improved prediction (c-statistic 0.7 to 0.74) of #cvMI by #YesCCT over & above clinical factors & plaque burden in the SCOT-HEART trial. jacc.org/doi/10.1016/j.jcmg.… #JACCIMG
Márton Kolossváry retweeted
REPRIEVE trial: People with HIV are at increased risk of cardiovascular events due to noncalcified coronary plaque (NCP); pitavastatin reduces MACE and NCP volume, likely through collagen pathways, independent of LDL-C levels. ja.ma/3FGp2Sa @reprievetrial
It is a huge honor to have received this years JACC Imaging award 🏆named after Prof. Narula.
Shout out to the #SCOTHEART team for making this possible!
Stay tuned! I have some every exciting projects coming later this year, that hope to transform how we do CV research 🔬
#JACCIMG honors Drs. Márton Kolossváry & Andrew Lin with the Jagat Narula Award for their groundbreaking research on coronary plaque radiomic phenotypes predicting fatal or nonfatal MI! 🎉
📎: jacc.org/doi/10.1016/j.jcmg.…
#ACC25 #TheFaceOfCardiology #cvMI #cvImaging @MKolossvary
There are so many configurations how plaque components may be distributed in plaques. Why wouldn’t it matter?
It’s time to accept that not only quantity, but also quality that is important 🫀
Radiomics – seeing deeper into CCT plaque? Radiomics-based precision phenotyping of coronary plaque morphology improved prediction (c-statistic 0.7 to 0.74) of #cvMI by #YesCCT over & above clinical factors & plaque burden in the SCOT-HEART trial. jacc.org/doi/10.1016/j.jcmg.… #JACCIMG
